

## ArcticZymes Technologies ASA: Primary insider exercising options

Tromsø, Norway, 10<sup>th</sup> December 2021 – With reference to stock exchange announcement regarding capital increase and exercise of options published today, 10<sup>th</sup> December 2021, CEO Jethro Holter has exercised 200,000 options at a strike price of NOK 8,00 per share. CEO Jethro Holter has intention to sell 120,000 shares to cover the tax obligation and the strike price following the exercise.

Following the transactions, CEO Jethro Holter has 200.564 shares and 0 options in ArcticZymes Technologies ASA

The information included in this announcement is such that the Company is required to disclose in accordance with the EU Market Abuse Regulation (MAR) section and 19 and section 5-12 of the Norwegian Securities Trading Act.

The announcement is made by CFO Børge Sørvoll, 10 December 2021, at 1258 CET.

For more information, please contact:

**ArcticZymes Technologies**

CFO, Børge Sørvoll

Tel: +47 95 29 01 87

ir@arcticzymes.com

### About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: [www.arcticzymes.com](http://www.arcticzymes.com).